Text
We started by listening
Screening is not about expecting bad news. It is about reducing uncertainty, and giving you and your clinician more options while there are more options to have.
Scott Tackett
CEO
Over the past several weeks, we’ve shared the stories of people whose lives have been shaped by cancer.
Each experience has been different. But together, they have reinforced the importance of putting people at the centre of how we think about earlier detection.
At AIRA Sciences, five elements have helped shape the development of AIR-DS Lung Test:
Accuracy. Affordability. Accessibility. Availability. Accommodation.
Because scientific performance is only part of the picture. Earlier detection also has to consider the people it is intended to reach and the healthcare environments in which it will be used in.
That is what these stories have brought to life.
Thank you to everyone who has trusted us with their story.
Anna R., Bryan LeBlanc, Lisa Gulley, Heather A. Valentine and Ken Krings
Originally shared on LinkedIn
Join the conversation and see how others have responded.
Older
Advancing infrared applications for earlier detection — beginning with lung cancer.
AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.